LAUSR

Abstract Objective This qualitative interview study explored the preferences of people living with schizophrenia or bipolar I disorder (BP-I), caregivers, and prescribers regarding the features of long-acting injectable (LAI) antipsychotics, as well as factors influencing preferences for a hypothetical LAI administered once every 2 months. Methods Trained moderators conducted online video interviews with stable adult patients with schizophrenia or BP-I receiving a once-monthly LAI, caregivers, and prescribers in the United States and Canada. The interview transcripts were analyzed for themes. Results Twelve patients, five caregivers, and five prescribers were included in the schizophrenia and BP-I samples. For patients and caregivers, an ideal treatment was efficacious, administered less often than a once-monthly LAI, and had minimal or no side-effects. Important LAI features included staying on the same medication, choice of injection site, and dosing frequency. Patients and caregivers viewed a once-every-2-months LAI positively, due to fewer appointments and reduced injection impact, but noted concerns about its effectiveness and potential side-effects. When prescribing LAIs, prescribers considered patient- and treatment-related factors, access, and control. The potential for greater patient freedom and stability with a once-every-2-months LAI was noted, but a loss of dosing control was a concern. Several differences between schizophrenia and BP-I samples were identified, including the level of patient/caregiver involvement in treatment decisions and unique treatment goals. Conclusions People living with schizophrenia or BP-I, caregivers, and prescribers in the United States and Canada generally had favorable views of LAIs administered once every 2 months. Quantitative follow-up research that extends these findings is warranted.